Please assess the completion status of the following clinical trial:

Trial Title: Insulin Resistance in Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years old Controls:~  * otherwise healthy Case subjects: NAFLD on liver biopsy within the past 3 years or presumed NAFLD with otherwise unexplained elevated ALT and fatty liver by CT or ultrasound~* Able to comply with taking 3 pills a day for 6 months and follow-up safety visits~Exclusion Criteria:~* Controls:~  * history or evidence of hepatic steatosis~* Cases:~  * Cirrhosis on liver biopsy or by clinical exam or fibrosis score~ * Causes of liver dysfunction other than NASH~* Use of medications associated with hepatic steatosis:~  * glucocorticoids~ * estrogens~ * tamoxifen~ * amiodarone~ * accutane~ * sertraline~* Use of medications that cause insulin resistance:~  * niacin~ * glucocorticoids~ * anti-HIV drugs or atypical antipsychotics~* Use of lipid-lowering medications except stable dose statin~* Use of anti-NASH drugs such as:~  * ursodeoxycholic acid~ * betaine milk thistle~* Use of coumadin~* Use of nitrates~* Significant alcohol consumption:~  * Average \>20 grams/day~* In subjects with diabetes~  * a HbA1c \>7.5% or use of insulin~ * metformin~ * rosiglitazone or pioglitazone~* Liver transaminases:~  * Cases: ALT \>5x upper limit of normal~ * Controls: ALT or AST above the normal range~* Iron saturation \>50%~* Creatinine \>1.5 mg/dl for men and \>1.4 mg/dl for women~* Hematocrit \<33%~* Pregnancy or lactation~* Significant weight loss within the past 6 months for controls, or since the liver biopsy for case subjects, history of significant coronary artery disease or congestive heart failure~* Retinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
- Rosiglitazone Arm (Type: EXPERIMENTAL): rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
- Fenofibrate Arm (Type: EXPERIMENTAL): micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid

Based on this trial design, predict the completion outcome and termination type (if applicable).